“Memorial Sloan Kettering really does seem to be taking this seriously and this document, I think, shows it,” he said, referring to the hospital’s revised policies. “Kudos to them.”

At the staff meeting, Mark P. Goodman, co-chairman of the law firm’s commercial litigation group, told doctors that the review found “a number of instances of serious noncompliance with M.S.K.’s conflict-of-interest policies,” according to a recording. A spokesman for the hospital, Mike Morey, declined to provide a copy of the Debevoise firm’s findings.

The conflicts and some profit-making deals — which were not specified at the meeting — did not occur through intentional misconduct, Mr. Goodman said. Rather, the review exposed inadequate oversight and a lack of established protocols for examining whether employees’ and executives’ affiliations with corporations could result in biased results that favored a company’s products.

Mr. Goodman also said the review, involving interviews with 36 current and former employees and board members and an examination of 25,000 documents, did not find that the ethical shortcomings had hurt patients or compromised research. In an email, Mr. Goodman disputed the characterization of the findings as violations of rules and said the report did not conclude that top officials acted in a concerted way. In his presentation, he referred instead to “noncompliance” with hospital policies and to instances where executives appeared not to have followed existing policies.

Scott Stuart, chairman of the cancer center’s Boards of Overseers and Managers, said in an emailed statement: “We took a deep and honest look at what went wrong at our own institution, examined what was occurring in the wider cancer research community, and are putting in place best practices that will not only allow us to learn from our mistakes, but will contribute to best practices for the wider research community.”

The cancer center has been reeling from the series of reports by The Times and ProPublica, including that its chief medical officer, Dr. José Baselga, had failed to disclose millions of dollars in payments from drug and health care companies in dozens of articles in medical journals.